Analyzing plasma metabolites for diagnosing multiple cancers
Identification and Validation of Plasma Diagnostic Biomarkers for Multi-Cancer Based on Metabolomics: A Multi-Center Clinical Research and Validation Trial
Beijing Friendship Hospital · NCT06363123
This study is testing if analyzing blood samples can help find early signs of different types of cancer, like lung and breast cancer, to improve screening for people at high risk.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2700 (estimated) |
| Sex | All |
| Sponsor | Beijing Friendship Hospital (other) |
| Drugs / interventions | chemotherapy |
| Locations | 4 sites (Beijing, Beijing and 3 other locations) |
| Trial ID | NCT06363123 on ClinicalTrials.gov |
What this trial studies
This observational study aims to analyze plasma samples from patients with various cancers using advanced mass spectrometry and metabolomics techniques. The researchers will create a comprehensive database of plasma metabolites to identify potential biomarkers for early diagnosis of multiple cancers, including lung, breast, colorectal, thyroid, and gastric cancers. By dividing samples into modeling and testing cohorts, the study will utilize bioinformatics to screen and validate metabolic markers that could enhance early cancer detection. The ultimate goal is to establish a safer and more sensitive screening method for individuals at high risk of multi-cancer.
Who should consider this trial
Good fit: Ideal candidates include individuals aged 45 and older with a confirmed diagnosis of multiple cancers and complete clinical data.
Not a fit: Patients who have received prior anti-tumor treatments or have other systemic tumors may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved early detection methods for multiple types of cancer, potentially increasing survival rates.
How similar studies have performed: Other studies utilizing metabolomics for cancer diagnosis have shown promising results, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Multi-Cancer Group: * Patients with a confirmed diagnosis based on the clinical "gold standard". * Collection of plasma samples prior to treatment. * Availability of complete clinical data. * Control Group: * Individuals with no abnormalities in routine physical examinations and relevant clinical tests. * Age ≥ 45 years. * Availability of complete clinical data. Exclusion Criteria: * Previous reception of anti-tumor treatments (including radiotherapy, chemotherapy, etc.) before blood collection. * Coexistence of other systemic tumors. * Absence of plasma sample collection before treatment. * Pregnancy status. * No clear evidence of histopathological diagnosis (not applicable to the control group based on this criterion). * Patients with severe acute infections. * Patients with severe anemia. * Patients with severe liver or kidney dysfunction. * Patients with autoimmune deficiency diseases. * Patients with Hyperlipidemia. * Patients received contrast agent injection before blood draw. * Patients with psychiatric disorders.
Where this trial is running
Beijing, Beijing and 3 other locations
- Cancer Hospital Chinese Academy of Medical Sciences — Beijing, Beijing, China (RECRUITING)
- Beijing Friendship Hospital, Capital Medical University — Beijing, Beijing, China (RECRUITING)
- Hebei Tumor Hospital — Shijiazhuang, Hebei, China (RECRUITING)
- Zhejiang Cancer Hospital — Hangzhou, Zhejiang, China (RECRUITING)
Study contacts
- Principal investigator: Li Min, Ph.D. — Beijing Friendship Hospital
- Study coordinator: Li Min, Ph.D.
- Email: minli@ccmu.edu.cn
- Phone: +86 13552652141
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Lung Cancer, Breast Cancer, Colorectal Cancer, Thyroid Cancer, Gastric Cancer, Cervical Cancer, Liver Cancer, Pancreatic Cancer